Recurrent implantation failure (RIF)

  • 暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    简介:已经研究了许多策略来解决复发性植入失败(RIF)和增强子宫内膜容受性。然而,就最佳干预措施达成一致仍然遥不可及。我们的调查努力评估低水平激光治疗(LLLT)对经历了至少三个不成功的胚胎移植周期(ET)的个体的妊娠结局的影响。方法:在我们的随机单盲临床试验中,我们纳入了30名具有RIF病史的女性,她们符合冻融胚胎移植(FET)的条件.通过随机分配序列,参与者分为两组。使用NewAgeBIOLASER装置(NewAgeCo.,意大利)具有900毫瓦的功率输出和850nm的波长。照射疗程是在腹下区域经腹进行的。考虑的结果是生化妊娠,血液妊娠试验呈阳性,和临床妊娠,通过超声检查孕囊的可视化确认。结果:受试者平均年龄34.17岁,他们之前经历了三到七次胚胎移植。激光治疗组与对照组之间的基本特征没有显着差异。然而,与对照组相比,激光治疗组的生化和临床妊娠率均升高(46.7%vs.33.3%;P==0.710和33.3%vs.20.0%;分别P=0.682)。结论:据我们所知,本研究是第一项单盲随机临床试验,旨在评估LLLT预处理对RIF患者的有效性.研究结果表明,LLLT可能会提高RIF患者的生化和临床妊娠率。
    Introduction: Numerous strategies have been investigated for addressing recurrent implantation failure (RIF) and enhancing endometrial receptivity, yet agreement on the optimal intervention remains elusive. Our investigation endeavors to assess the effect of low-level laser therapy (LLLT) on pregnancy outcomes in individuals who have undergone a minimum of three unsuccessful embryo transfer cycles (ET). Methods: In our randomized single-blinded clinical trial, we enrolled thirty females with a medical history of RIF who were eligible for frozen-thawed embryo transfer (FET). Through a random allocation sequence, the participants were divided into two groups. The LLLT was performed one cycle before blastocyst transfer in 15 cases using a New Age BIOLASER device (New Age Co., Italy) with a 900-milliwatt power output and an 850-nm wavelength. The irradiation sessions were conducted transabdominal on the hypogastric area. The considered outcomes were biochemical pregnancy, identified by a positive blood pregnancy test, and clinical pregnancy, confirmed through visualization of the gestational sac using ultrasonography. Results: The mean age of the subjects was 34.17 years, and they had undergone three to seven previous embryo transfers. There was no significant difference in basic characteristics between the group undergoing laser treatment and the control group. However, the laser-treated group exhibited elevated rates of both biochemical and clinical pregnancies compared to the control group (46.7% vs. 33.3%; P==0.710 and 33.3% vs. 20.0%; P=0.682 respectively). Conclusion: To our knowledge, this study represents the first single-blinded randomized clinical trial to assess the effectiveness of LLLT pretreatment in individuals with RIF. The findings propose that LLLT may potentially enhance biochemical and clinical pregnancy rates among RIF patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目标:在当代社会,社会活跃的女性越来越多地为以后的生活计划生育。高龄患者的生育结果,即使是捐卵,通常由于子宫内膜老化而不理想。复发性着床失败(RIF)是辅助生殖技术(ART)的核心问题之一。尤其是高龄患者。高品质,整倍体胚胎以及胚胎期与子宫内膜内膜之间的同步对于积极结局至关重要。该研究旨在根据具有挑战性生殖史的高龄患者的子宫内膜容受性分析(ERA),通过个性化胚胎移植(pET)改善ART结果。和RIF通过利用,供体卵母细胞和胚胎非整倍性(PGT-A)的植入前遗传测试。
    方法:随机,2020年至2023年进行了对照观察性随访研究。在获得知情同意后,选择RIF患者320例。根据随机化原则的一致应用,将患者分为研究组和对照组。对照组2单独选择。研究组包括接受PGT-A和ERA的患者,35-45岁,平均年龄为40.5±3.7岁。对照组1包括接受PGT-A的患者,35-45岁,平均年龄为40±4.2岁。对照组2包括接受PGT-A和ERA的患者,年龄小于35岁,平均年龄31.6±2.2岁。
    结果:结果表明,ERA可以改善高龄患者的植入和妊娠结局,特别是那些有RIF的。研究组妊娠率明显高于对照组(77.9%),与对照组1(57.6%)相比(p=0.0007),与对照组2(77.3%)相比无显着差异(p=0.94)。研究组的种植率(54.1%)高于对照组1(39.4%)(p=0.0009),研究组与对照2组之间无显著差异(50%,p=0.87)。研究组活产率也较高(71.3%),与对照组1相比(39.4%)(p<0.0001)。研究组与对照2组差异无统计学意义(65.9%,p=0.50)。
    结论:由ERA指导的pET可显著改善妊娠,植入,以及具有挑战性生殖史的高龄患者的活产率。在ERA指导下,pET提供的ART结局在高龄患者和年轻患者之间没有显著差异.
    OBJECTIVE: In contemporary society, socially active women are increasingly planning their fertility for later in life. The fertility outcomes for advanced-age patients, even with egg donation, are often suboptimal due to endometrial aging. Recurrent implantation failure (RIF) is one of the core problems for assisted reproductive technology (ART), especially for advanced-age patients. High-quality, euploid embryos and synchronization between the embryonic stage and the uterine endometrial lining are crucial for positive outcomes. The study aims to improve ART outcomes with personalized embryo transfer (pET) according to endometrial receptivity analysis (ERA) in advanced-age patients with challenging reproductive histories, and RIF by utilizing, donor oocytes and preimplantation genetic testing for aneuploidy (PGT-A) for embryo testing.
    METHODS: A randomized, controlled observational follow-up study was conducted from 2020 to 2023. After obtaining informed consent, 320 patients with RIF were selected. Patients were allocated into the study group and control group 1 based on consistent application of randomization principles, while control group 2 was selected separately. The study group included patients undergoing PGT-A and ERA, aged 35-45 years, with a mean age of 40.5±3.7 years. Control group 1 comprised patients undergoing PGT-A, aged 35-45 years, with a mean age of 40±4.2 years. Control group 2 consisted of patients undergoing PGT-A and ERA, aged less than 35 years, with a mean age of 31.6±2.2 years.
    RESULTS: Results suggest that ERA may improve implantation and pregnancy outcomes in advanced-age patients, particularly those with RIFs. The pregnancy rate was significantly higher in the study group (77.9%), compared to control group 1 (57.6%) (p=0.0007), and no significant difference compared to control group 2 (77.3%) (p=0.94). The implantation rate was higher in the study group (54.1%) than in control group 1 (39.4%) (p=0.0009), and there was no significant difference between the study group and control group 2 (50%, p=0.87). The live birth rate was also higher in the study group (71.3%), compared to control group 1 (39.4%) (p<0.0001). There were no significant differences between the study group and control group 2 (65.9%, p=0.50).
    CONCLUSIONS: pET guided by ERA significantly improves pregnancy, implantation, and live birth rates in advanced-age patients with challenging reproductive histories. pET provides ART outcomes with no significant difference between advanced-age patients and younger patients with pET guided by ERA.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:反复植入失败(RIF)患者子宫内膜增殖细胞核抗原(PCNA)的表达是否调节子宫内膜容受性?
    结论:高丰度的PCNA减弱RIF患者的子宫内膜粘附能力和蜕膜化。
    背景:已在多种不育相关疾病中发现了PCNA的异常表达。然而,PCNA在RIF患者子宫内膜容受性和子宫内膜蜕膜化中的表达模式和作用尚不清楚。
    方法:我们分析了24例RIF患者和24例健康女性子宫内膜分泌中期组织中PCNA的表达。此外,在月经周期正常的妇女的增殖期和分泌中期子宫内膜组织样本中以及在正常早期妊娠期间从10名妇女的蜕膜组织样本中测量PCNA表达水平(每组n=10)。使用BeWo球体研究PCNA在子宫内膜粘附能力和子宫内膜蜕膜化中的功能和调节机制,石川细胞,和人子宫内膜基质细胞(HESC)。
    方法:用RT-qPCR方法分析RIF患者和正常子宫内膜妇女子宫内膜中期分泌组织、月经周期不同阶段子宫内膜组织和蜕膜化组织中PCNA的表达,westernblot,免疫组织化学染色(IHC)。此外,直接附着在Ishikawa细胞单层上的BeWo球体的数量,以及潜在的分子机制,在过表达PCNA的细胞和对照组之间进行比较。此外,研究了PCNA对HESCs蜕膜化的影响及其调控机制。
    结果:我们的研究结果表明,RIF患者子宫内膜中部分泌组织中PCNA的丰度明显高于子宫内膜健康的女性。PCNA的表达在月经周期的增殖阶段增加,但在分泌中期和蜕膜组织中逐渐降低。有趣的是,PCNA在人子宫内膜上皮细胞(HEEC)和HESC中均有表达。在石川牢房里,PCNA过表达通过抑制粘附分子(E-钙黏着蛋白和整联蛋白β3)的表达和激活FAK/桩蛋白信号通路而显著降低子宫内膜粘附能力。此外,在HESCs中,PCNA过表达通过激活AKT/β-连环蛋白信号通路并通过上调ZO-1和occludin表达来增加细胞之间的紧密连接来减弱子宫内膜蜕膜化。此外,PCNA-ELAVL1相互作用通过在蜕膜化HESC中的共免疫沉淀来确认。
    方法:不适用。
    结论:PCNA的功能分析受到人子宫内膜组织数量的限制。需要更大的样本量来进一步探索PCNA在胚胎植入过程中的潜在作用。此外,目前的结果应该谨慎对待,因为只有少数在RIF患者人群中移植的胚胎接受了胚胎染色体非整倍体(PGT-A)的植入前遗传学检测,尽管胚胎倍性测试对无法解释的RIF的诊断具有重要意义。
    结论:高PCNA表达减弱RIF患者的子宫内膜粘附能力和蜕膜化。这些发现为植入失败发生的潜在机制提供了新的见解。
    背景:这项工作得到了国家自然科学基金(82101698)的支持,山东省自然科学基金(ZR2021MH012),《烟台市科技计划》(2023YD021、2022YD031)。作者没有利益冲突要披露。
    背景:不适用。
    OBJECTIVE: Does the expression of proliferating cell nuclear antigen (PCNA) in the endometrium regulate endometrial receptivity in patients with recurrent implantation failure (RIF)?
    CONCLUSIONS: A high abundance of PCNA attenuates endometrial adhesive capacity and decidualization in patients with RIF.
    BACKGROUND: Aberrant expression of PCNA has been discovered in multiple infertility-related disorders. However, the expression pattern and role of PCNA in the establishment of endometrial receptivity and endometrial decidualization in patients with RIF remain unclear.
    METHODS: We analysed the expression of PCNA in mid-secretory endometrial tissues from 24 patients with RIF and 24 healthy women. Additionally, PCNA expression levels were measured in proliferative and mid-secretory phase endometrial tissue samples from women with regular menstrual cycles and in decidual tissue samples taken from ten women during normal early pregnancy (n = 10 per phase for each group). The function and regulatory mechanisms of PCNA in endometrial adhesive capacity and endometrial decidualization were investigated using BeWo spheroids, Ishikawa cells, and human endometrial stromal cells (HESCs).
    METHODS: The expression of PCNA in mid-secretory endometrial tissues of patients with RIF and women with normal endometrium and in endometrial tissue at different stages of the menstrual cycle and in decidualized tissues was analysed by RT-qPCR, western blot, and immunohistochemistry staining (IHC). Furthermore, the number of BeWo spheroids directly attached to the Ishikawa cell monolayers, and the potential molecular mechanisms involved, were compared between cells overexpressing PCNA and a control group. Additionally, the effect and regulatory mechanisms of PCNA on the decidualization of HESCs in vitro were investigated.
    RESULTS: Our findings indicated that the abundance of PCNA was dramatically greater in mid-secretory endometrial tissues from patients with RIF than in those from women with healthy endometrium. The expression of PCNA increased in the proliferative phase of the menstrual cycle but decreased gradually in the mid-secretory phase and in decidual tissues. Interestingly, PCNA was expressed in both human endometrial epithelial cells (HEECs) and HESCs. In Ishikawa cells, PCNA overexpression dramatically reduced the endometrial adhesive capacity by inhibiting the expression of adhesion molecules (E-cadherin and integrin β3) and activating the FAK/paxillin signalling pathway. Furthermore, in HESCs, PCNA overexpression attenuated endometrial decidualization by activating the AKT/β-catenin signalling pathway and increasing tight junctions between cells by upregulating ZO-1 and occludin expression. In addition, PCNA-ELAVL1 interactions were confirmed by coimmunoprecipitation in decidualized HESCs.
    METHODS: N/A.
    CONCLUSIONS: The functional analysis of PCNA was limited by the number of human endometrial tissues. A larger sample size is required to further explore the potential roles of PCNA during embryo implantation. Moreover, the present results should be taken with caution, as only a few of the embryos that were transferred in RIF patients population underwent preimplantation genetic testing for embryonic chromosome aneuploidies (PGT-A), despite embryo ploidy testing being significant in the diagnosis of unexplained RIF.
    CONCLUSIONS: High PCNA expression attenuates endometrial adhesive capacity and decidualization in patients with RIF. These findings provide new insights into the potential mechanisms underlying the occurrence of implantation failure.
    BACKGROUND: This work was supported by the National Natural Science Foundation of China (82101698), Shandong Provincial Natural Science Foundation (ZR2021MH012), and the Science and Technology Plan of Yantai (2023YD021 and 2022YD031). The authors have no conflicts of interest to disclose.
    BACKGROUND: N/A.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Editorial
    完整的ART检查应在任何胚胎移植之前进行。
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    复发性植入失败(RIF)对辅助生殖技术(ART)结局构成了重大挑战。子宫内膜在胚胎着床中起着至关重要的作用,它的蛋白质表达谱在决定接受性时是不可或缺的。蛋白质组学已成为揭示子宫内膜容受性和RIF的分子复杂性的有价值的工具。本综述的目的是分析蛋白质组学对了解RIF女性子宫内膜蛋白表达的贡献。基于重要的蛋白质组学研究结果。使用与蛋白质组学相关的关键词以及与RIF相关的术语来搜索Medline/Pubmed数据库。本综述包括15项研究。已经发现几种蛋白质在子宫内膜接受期期间在可育妇女和患有RIF的妇女之间的子宫内膜活检和液体样品中表现出差异表达。在研究中,子宫内膜蛋白的分布差异很大。然而,膜联蛋白-6,孕激素受体,MMP-2和MMP-9在RIF妇女的子宫内膜中,在一项以上的研究中发现,某些蛋白质可能是子宫内膜容受性的有效生物标志物。蛋白质组学有助于了解RIF女性子宫内膜中的蛋白质表达,子宫内膜液中的蛋白质分析有望改善RIF的临床治疗。
    Recurrent implantation failure (RIF) poses a significant challenge in assisted reproductive technology (ART) outcomes. The endometrium plays a crucial role in embryo implantation, and its protein expression profile is integral in determining receptivity. Proteomics has emerged as a valuable tool in unraveling the molecular intricacies underlying endometrial receptivity and RIF. The aim of the present review is to analyze the contribution of proteomics to the understanding of endometrial protein expression in women with RIF, based on the results of significant proteomic studies. Medline/Pubmed databases were searched using keywords pertaining to proteomics combined with terms related to RIF. 15 studies were included in the present review. Several proteins have been found to exbibit differential expression in endometrial biopsies and fluid samples between fertile women and women with RIF during the receptive endometrial phase. The profile of endometrial proteins varied significantly among the studies. Nevertheless, similar changes in the expression levels of annexin-6, progesterone receptor, MMP-2, and MMP-9 in the endometrium of women with RIF, were found in more than one study indicating that certain proteins could potentially be effective biomarkers of endometrial receptivity. Proteomics contributes significantly to the understanding of protein expression in the endometrium of women with RIF and the analysis of proteins in endometrial fluid are promising for improving the clinical management of RIF.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    已经假设母胎相互作用涉及人白细胞抗原(HLA)。已经提出,配偶之间过度的HLA抗原共享是一种机制,导致母体对怀孕期间遇到的父系抗原反应性低下,从而导致流产。这项回顾性研究的参与者是访问Gunasheela外科和妇产医院的RIF和RPL夫妇,班加罗尔,印度从2019年11月到2022年9月。共有40对RIF夫妇和195对RPL夫妇被纳入研究。我们观察到DQB1*02:01:01等位基因与RIF和RPL的风险增加相关,而C*12:02:01等位基因仅增加RPL的风险。相反,DQB1*02:02:01和DQB1*06:03等位基因似乎对RPL和RIF都有保护作用。此外,观察到C*07:02:01等位基因对RPL具有保护性。总之,C*12:02:01和DQB1*02:01:01可能在RPL中起主要作用,这与其他研究一致,而DQB1*02:01:01是我们RIF组的风险等位基因。RPL组中的保护性等位基因C*07:02:01,DQB1*02:02:01和DQB1*06:03在RIF和RPL中,这是第一次被发现。等位基因频率在基于人群的研究中会有所不同,具体取决于队列的种族。荟萃分析和抗体测试将为是否以及如何将这些数据应用于临床实践提供更多见解。
    The maternal-fetal interaction has been hypothesized to involve the human leucocyte antigen (HLA). It has been suggested that excessive HLA antigen sharing between spouses is a mechanism causing maternal hyporesponsiveness to paternal antigens encountered during pregnancy and thus leading to a miscarriage. Participants in this retrospective study are RIF and RPL couples who visited Gunasheela Surgical and Maternity Hospital, Bangalore, India from November 2019 to September 2022. A total of 40 couples with RIF and 195 couples with RPL are included in the study. We observed that the DQB1*02:01:01 allele is associated with an increase in risk of both RIF and RPL, while the C*12:02:01 allele increases risk of only RPL. On the contrary, DQB1*02:02:01 and DQB1*06:03 alleles appear to be protective against both RPL and RIF. In addition, the C*07:02:01 allele was observed to be protective against RPL. In conclusion, C*12:02:01 and DQB1*02:01:01 could play a major role in RPL which is consistent with other studies, while DQB1*02:01:01 is the risk allele in our RIF group. The protective alleles C*07:02:01 in the RPL group, DQB1*02:02:01, and DQB1*06:03 in both RIF and RPL, were discovered for the first time. Allele frequencies will vary in population-based studies depending on the ethnicities of the cohort. Meta-analysis and antibody testing will provide additional insights on whether and how this data can be adopted into clinical practices.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    复发性植入失败(RIF)患者植入窗口(WOI)移位的分子机制尚不清楚。本研究旨在探索具有正常和移位WOI的子宫内膜的转录组特征,并确定RIF患者子宫内膜容受性(ER)异常和WOI移位的原因。
    在这项研究中,招募40例RIF患者,以子宫内膜容受性诊断(ERD)模型预测结果为指导,进行个性化胚胎移植(pET)。对pET后临床妊娠患者的子宫内膜进行转录组分析,以鉴定与WOI置换相关的差异表达基因(DEGs)。比较了来自HRT和自然周期子宫内膜的基因表达数据,以鉴定WOI期间ER相关基因的特定基因表达模式。
    ERD结果表明,在HRT周期的常规WOI(P5)中,有67.5%的RIF患者(27/40)未接受。RIF患者经ERD引导pET后临床妊娠率提高至65%(26/40),表明基于转录组的WOI预测的有效性。26例临床妊娠患者中,晚期P+5子宫内膜的基因表达谱(n=6),正常(n=10)和延迟(n=10)WOI组之间存在显着差异。此外,在3组的P+5子宫内膜中确定的10个DEGs参与免疫调节,跨膜转运和组织再生,可以准确地对不同WOI的子宫内膜进行分类。此外,大量ER相关基因在HRT周期的P+3、P+5、P+7子宫内膜和自然周期的LH+5、LH+7、LH+9子宫内膜显示出显著的相关性和相似的基因表达模式。
    我们的研究表明,在自然和HRT周期中,与ER相关的基因在WOI期间具有相似的基因表达模式,它们的异常表达与WOI位移有关。通过根据ERD结果调整ET时间来改善RIF患者的妊娠结局,证明了基于转录组的子宫内膜容受性评估和ERD模型的临床有效性的重要性。
    The molecular mechanisms underlying window of implantation (WOI) displacement in patients with recurrent implantation failure (RIF) remain unclear. This study aims to explore the transcriptomic signatures of endometrium with normal and displaced WOIs and to identify the causes of endometrial receptivity (ER) abnormalities and WOI displacement in RIF patients.
    In this study, 40 RIF patients were recruited and underwent personalized embryo transfer (pET) guided by the predicted results of endometrial receptivity diagnosis (ERD) model. Transcriptome analysis of endometrium from patients with clinical pregnancies after pET was performed to identify differentially expressed genes (DEGs) associated with WOI displacement. Gene expression data from HRT and natural cycle endometrium were compared to identify specific gene expression patterns of ER-related genes during WOI.
    The ERD results indicated that 67.5% of RIF patients (27/40) were non-receptive in the conventional WOI (P+5) of the HRT cycle. The clinical pregnancy rate in RIF patients improved to 65% (26/40) after ERD-guided pET, indicating the effectiveness of transcriptome-based WOI prediction. Among the 26 patients with clinical pregnancy, the gene expression profiles of P+5 endometrium from advanced (n=6), normal (n=10) and delayed (n=10) WOI groups were significantly different from each other. Furthermore, 10 DEGs identified among P+5 endometrium of 3 groups were involved in immunomodulation, transmembrane transport and tissue regeneration, which could accurately classify the endometrium with different WOIs. Additionally, a large number of ER-related genes showed significant correlation and similar gene expression patterns in P+3, P+5, and P+7 endometrium from HRT cycles and LH+5, LH+7, and LH+9 endometrium from natural cycles.
    Our study shows that ER-related genes share similar gene expression patterns during WOI in both natural and HRT cycles, and their aberrant expression is associated with WOI displacements. The improvement of pregnancy outcomes in RIF patients by adjusting ET timing according to ERD results demonstrates the importance of transcriptome-based endometrial receptivity assessment and the clinical efficiency of ERD model.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    反复植入失败(RIF)是辅助生殖技术(ART)的核心问题之一。高品质,整倍体胚胎以及胚胎期与子宫内膜内膜之间的同步对于积极结局至关重要。分子生物学技术已经显著改变了辅助生殖技术(ART)。许多面临不孕症问题的夫妇通过应用分子生物学方法成功地实现了健康婴儿的出生:非整倍性植入前遗传测试(PGT-A)和子宫内膜容受性分析(ERA)。探索年龄对子宫内膜测定的影响,如子宫内膜容受性测定(ERA)产生有价值的见解,包括确定植入窗口和制定个性化策略。作者介绍了一名42岁的女性,她经历过整倍体胚胎的RIF,加上MTHFR基因A1298C和C677T的遗传性血栓形成纯合突变。
    Recurrent implantation failure (RIF) is one of the core problems for assisted reproductive technology (ART). High-quality, euploid embryos and synchronization between the embryonic stage and the uterine endometrial lining are crucial for positive outcomes. Molecular biology techniques have significantly transformed assisted reproductive technology (ART). Numerous couples facing infertility issues have successfully achieved the birth of healthy infants through the application of molecular biology methods: preimplantation genetic testing for aneuploidy (PGT-A) and endometrial receptivity analysis (ERA). Exploring the impact of age on endometrial assays like the endometrial receptivity assay (ERA) yields valuable insights, including the determination of the implantation window and the development of personalized strategies. The authors present the case of a 42-year-old woman who has experienced RIF with euploid embryos, coupled with a hereditary thrombophilia homozygous mutation in the MTHFR genes: A1298C and C677T.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Randomized Controlled Trial
    OBJECTIVE: To observe the effects of acupuncture combined with Chinese herbal medication on pregnancy outcomes in patients with recurrent implantation failure (RIF) infertility of kidney deficiency and blood stasis, and to explore its effects on the protein expression of serum p38MAPK and JAK/STAT.
    METHODS: Sixty-two patients with RIF infertility of kidney deficiency and blood stasis who were scheduled for artificial cycle frozen-thawed embryo transfer were randomly divided into an observation group (31 cases, 4 cases dropped out) and a control group (31 cases, 3 cases were eliminated). The patients in the control group were treated with conventional artificial cycle frozen-thawed embryo transfer. On the basis of the control group, the patients in the observation group were treated with acupuncture combined with Chinese herbal medication. Acupuncture was applied at Baihui (GV 20), Guanyuan (CV 4) and bilateral Neiguan (PC 6), Zigong (EX-CA 1), Guilai (ST 29), Zusanli (ST 36), Taichong (LR 3), Shenshu (BL 23), Ciliao (BL 32), with each session lasting for 30 minutes, once every other day. Chinese herbal medication was administered to Bushen Huoxue (tonifing the kidney and activating blood circulation) decoction, with one dose per day, starting from the 3rd to 5th day of the menstrual cycle and continuing until 1 day before embryo transfer. Clinical pregnancy rate, embryo implantation rate, live birth rate, and biochemical pregnancy rate were compared between the two groups. TCM symptom score, platelet count (PLT), and plasma D-dimer level were assessed before treatment and 1 day before embryo transfer. Western blot method was used to detect the expression of serum P38MAPK, JAK, and STAT proteins before treatment and 1 day before embryo transfer.
    RESULTS: In the observation group, the clinical pregnancy rate, embryo implantation rate, and live birth rate were higher (P<0.05), while the biochemical pregnancy rate was lower (P<0.05) than those in the control group. One day before embryo transfer, both groups showed a decrease in TCM symptom scores, PLT, and plasma D-dimer levels compared to those before treatment (P<0.05), and the observation group had lower TCM symptom scores and plasma D-dimer levels than the control group (P<0.05). One day before embryo transfer, the expression levels of serum p38MAPK, JAK, and STAT proteins in both groups were lower than those before treatment (P<0.05), and the observation group had lower serum p38MAPK protein expression than the control group (P<0.05).
    CONCLUSIONS: Acupuncture combined with Chinese herbal medication can improve the clinical pregnancy rate, embryo implantation rate, live birth rate, and reduce the biochemical pregnancy rate in RIF infertility patients of kidney deficiency and blood stasis. Its mechanism of action may be related to down-regulating plasma D-dimer level and protein expression of serum p38MAPK.
    目的: 观察针刺联合中药对反复种植失败(RIF)不孕患者妊娠结局及血清p38丝裂原活化蛋白激酶(MAPK)、Janus激酶(JAK)/信号转导和转录激活因子(STAT)蛋白表达的影响。方法: 将62例拟行人工周期冻融胚胎移植的肾虚血瘀型RIF不孕患者随机分为观察组(31例,脱落4例)和对照组(31例,剔除3例)。对照组予人工周期冻融胚胎移植常规方案治疗。在对照组基础上,观察组予针刺联合中药治疗,针刺穴取百会、关元,双侧内关、子宫、归来、足三里、太冲、肾俞、次髎,每次30 min,隔日1次;中药予补肾活血方,每日1剂。于月经第3~5天开始,治疗至移植前1 d。比较两组患者临床妊娠率、胚胎种植率、活产率、生化妊娠率,治疗前及移植前1 d中医症状评分、血小板计数(PLT)、血浆D-二聚体含量。于治疗前及移植前1 d采用Western blot法检测两组患者血清p38MAPK、JAK、STAT蛋白表达。结果: 观察组临床妊娠率、胚胎种植率、活产率高于对照组(P<0.05),生化妊娠率低于对照组(P<0.05)。移植前1 d,两组中医症状评分、PLT、血浆D-二聚体含量较治疗前降低(P<0.05),观察组中医症状评分、血浆D-二聚体含量低于对照组(P<0.05)。移植前1 d,两组患者血清p38MAPK、JAK、STAT蛋白表达均少于治疗前(P<0.05),观察组血清p38MAPK蛋白表达少于对照组(P<0.05)。结论: 针药结合能提高肾虚血瘀型RIF不孕患者的临床妊娠率、胚胎种植率、活产率,降低生化妊娠率,其作用机制可能与降低血浆D-二聚体含量及下调血清p38MAPK蛋白表达有关。.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号